- GILD -1.31% TFC +0.56%
Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 15 Best Boring Dividend Stocks to Buy.
Gilead (GILD) Earns Buy Rating at Truist as HIV Franchise Continues to Deliver On November 24, Truist’s Gregory Renza initiated coverage of Gilead Sciences, Inc. (NASDAQ:GILD) with a Buy rating and set a price target of $140, slightly below the previous $145, as reported by The Fly. In his note to investors, he highlighted the ongoing strength of the company’s HIV portfolio and the solid progress of its next-generation programs, which he believes support a healthy long-term outlook. Truist also sees the company’s oncology efforts as an increasingly important driver of future growth.
Within its core business, Gilead Sciences, Inc. (NASDAQ:GILD) continued to post strong results. Biktarvy, its flagship HIV treatment, delivered $3.7 billion in sales, up 6% from the same period last year. Descovy, another key HIV therapy, saw revenue climb 20% year over year to $701 million. Although some investors worry that Gilead relies too heavily on its HIV franchise, the company has been steadily working to broaden its portfolio.
Its liver disease treatments also contributed to growth, with sales rising 12% year over year to $819 million. Overall, the company’s underlying business remains solid, and its diversification strategy should help reduce its dependence on the HIV segment over time.
Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company engaged in discovering, developing, and commercializing innovative medicines for unmet medical needs.
While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Best Long Term Stocks to Buy According to Reddit and 15 Best Stocks to Buy for Medium Term
Disclosure: None.
Terms and Privacy Policy Privacy Dashboard More Info
